Patents Assigned to John Wayne Cancer Institute
-
Publication number: 20220213126Abstract: Disclosed herein are compounds and methods for treating cancer and neurodegenerative diseases. In some examples, the compounds increase autophagy.Type: ApplicationFiled: April 23, 2020Publication date: July 7, 2022Applicant: John Wayne Cancer InstituteInventors: Venkata Yenugonda, Santosh Kesari
-
Patent number: 10987037Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.Type: GrantFiled: September 23, 2015Date of Patent: April 27, 2021Assignee: JOHN WAYNE CANCER INSTITUTEInventors: David Hoon, Bret Taback, Samuel Shaolian
-
Patent number: 9758829Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.Type: GrantFiled: June 24, 2013Date of Patent: September 12, 2017Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer InstituteInventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
-
Patent number: 9567640Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.Type: GrantFiled: May 11, 2012Date of Patent: February 14, 2017Assignee: JOHN WAYNE CANCER INSTITUTEInventor: Dave S. B. Hoon
-
Patent number: 9556491Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.Type: GrantFiled: February 26, 2008Date of Patent: January 31, 2017Assignee: JOHN WAYNE CANCER INSTITUTEInventor: Dave S. B. Hoon
-
Patent number: 9410206Abstract: Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer.Type: GrantFiled: November 30, 2012Date of Patent: August 9, 2016Assignee: JOHN WAYNE CANCER INSTITUTEInventors: Dave S. B. Hoon, Laurent Lessard
-
Patent number: 9162884Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis.Type: GrantFiled: December 21, 2011Date of Patent: October 20, 2015Assignee: John Wayne Cancer InstituteInventors: David Hoon, Bret Taback, Samuel Shaolian
-
Patent number: 9156898Abstract: The invention discloses a method of identifying a gene associated with stage III primary cancer or lymph node metastasis. The genes so identified include CAV1, CST3, LIMK1, MMP2, MMP15, VEGF, ETV4, MMP9, PIK3C2B, and SERPIN1. Also disclosed are methods for diagnosis, prognosis, and treatment of cancer. The invention further discloses compositions for preventing and treating diseases.Type: GrantFiled: September 23, 2011Date of Patent: October 13, 2015Assignee: John Wayne Cancer InstituteInventor: Richard Essner
-
Patent number: 9074253Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.Type: GrantFiled: September 27, 2013Date of Patent: July 7, 2015Assignee: JOHN WAYNE CANCER INSTITUTEInventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20150176072Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.Type: ApplicationFiled: June 24, 2013Publication date: June 25, 2015Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer InstituteInventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
-
Publication number: 20150071852Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.Type: ApplicationFiled: April 10, 2014Publication date: March 12, 2015Applicant: John Wayne Cancer InstituteInventor: Xiaojiang Cui
-
Publication number: 20140206961Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe.Type: ApplicationFiled: October 28, 2013Publication date: July 24, 2014Applicant: John Wayne Cancer InstituteInventors: David Hoon, Bret Taback, Samuel Shaolian
-
Publication number: 20140134626Abstract: In one embodiment, a method of theranostic classification of a breast cancer tumor is provided, comprising obtaining a breast cancer tumor sample from a subject, detecting an expression level of FOXC1, comparing the expression level of FOXC1 to a predetermined cutoff level, and classifying the breast cancer tumor sample as belonging to a theranostic basal-like breast cancer tumor subtype or a theranostic hybrid basal-like breast cancer tumor subtype when the expression level of FOXC1 is higher than the predetermined cutoff level. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.Type: ApplicationFiled: September 27, 2013Publication date: May 15, 2014Applicant: JOHN WAYNE CANCER INSTITUTEInventors: Partha S. Ray, Sanjay Bagaria, Xiaojiang Cui, Jinhua Wang
-
Publication number: 20130345144Abstract: Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer.Type: ApplicationFiled: August 7, 2009Publication date: December 26, 2013Applicant: JOHN WAYNE CANCER INSTITUTEInventors: Dave S. B. Hoon, Naoyuki Umetani
-
Patent number: 8569044Abstract: The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe.Type: GrantFiled: August 8, 2011Date of Patent: October 29, 2013Assignee: John Wayne Cancer InstituteInventors: David Hoon, Bret Taback, Samuel Shaolian
-
Publication number: 20130231259Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GaINAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GaINAcT, CK20, and ?-HCG.Type: ApplicationFiled: December 11, 2012Publication date: September 5, 2013Applicant: JOHN WAYNE CANCER INSTITUTEInventors: Dave S.B. Hoon, Hiroya Takeuchi
-
Publication number: 20120295258Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.Type: ApplicationFiled: May 11, 2012Publication date: November 22, 2012Applicant: JOHN WAYNE CANCER INSTITUTEInventor: Dave S.B. Hoon
-
Patent number: 8288099Abstract: The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen.Type: GrantFiled: December 14, 2009Date of Patent: October 16, 2012Assignee: John Wayne Cancer InstituteInventors: Dave S. B. Hoon, Michiel de Maat
-
Publication number: 20120148561Abstract: The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.Type: ApplicationFiled: February 17, 2012Publication date: June 14, 2012Applicant: JOHN WAYNE CANCER INSTITUTEInventors: Dave S.B. Hoon, Minoru Kitago
-
Publication number: 20120088683Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.Type: ApplicationFiled: October 2, 2011Publication date: April 12, 2012Applicant: John Wayne Cancer InstituteInventor: Dave S. B. Hoon